



Amarantus
BioSciences

CONTACTS:

Susan Kim
212-203-4433
pr@amarantus.com

Amarantus BioSciences Announces Completion of Capital Restructuring

SUNNYVALE, CA – June 14, 2011 – Amarantus BioSciences, Inc. (OTCBB:AMBS), a California-based biotechnology company developing first-in-class proteins, today announced the successful completion of the Company's capital restructuring initiatives, including a 25-for-1 forward stock split (the "Forward Stock Split"), which was previously approved by its stockholders and announced on June 2, 2011. According to FINRA's confirmation, the Forward Stock Split became effective on June 13, 2011 (the "Effective Date"). As of the Effective Date, and as a result of the Forward Stock Split, there are approximately 67,000,000 shares issued and outstanding.

“By effecting the previously-announced forward stock split, Amarantus has created a more attractive capital structure, thereby enhancing our visibility in the public equity markets,” said Martin D. Cleary, Amarantus' Chairman and CEO. “Furthermore, today's announcement demonstrates our continued emphasis on aligning shareholders' interests with the solid execution of our business plan.”

Amarantus' lead product candidate, MANF, is a first-in-class, naturally-occurring therapeutic protein that has broad applications in the treatment of devastating human diseases related to protein misfolding and apoptosis, such as diabetes, cardiac ischemia and neurodegenerative diseases. With a combined market opportunity of \$350 billion, the Company is focused on executing successful pre-clinical programs in these indications for which there remains a significant unmet medical need.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is engaged in the research and development of first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases. The Company's most advanced product candidate, MANF, is a therapeutic protein indicated for the treatment of Parkinson's disease and Myocardial Infarction. Currently incubating at the Parkinson's Institute in Sunnyvale, CA, Amarantus BioSciences is the recipient of a research grant from The Michael J. Fox Foundation for Parkinson's Research. See www.amarantus.com.

Forward Looking Safe-Harbor Statement:

The information provided herein may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Exchange Act of 1934. These forward-looking statements are largely based on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Such forward-looking statements include, in particular, statements about our plans, strategies, business prospects, and the ongoing and future development of disease modifying treatments. These forward-looking statements may be identified by the use of terms and phrases such as "anticipates," "believes," "can," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "projects," "targets," "will," and similar expressions or variations of these terms and similar phrases. Additionally, statements concerning future matters such as planned research and development and the regulatory approval, marketing, and sale of planned future and other statements regarding matters that are not historical are forward-looking statements. Management cautions that these forward-looking statements relate to future events or our future financial performance and are subject to business, economic, and other risks and uncertainties, both known and unknown, that may cause actual results, levels of activity, performance or achievements of our business or our industry to be materially different from those expressed or implied by any forward-looking statements.

These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, including without limitation, the following: (a) the risk that our product candidate MANF, which is still under clinical development, may not obtain regulatory approval or be successfully commercialized; (b) the risk that extensive regulatory requirements may limit the scope of future sales or impede successful product commercialization even if we obtain regulatory approval for our product candidate; (c) the risk that we may be unable to arrange for the successful manufacture and commercial supply of our planned product; (d) the risk that MANF, if approved and brought to market, may not be accepted by the medical community; (e) the risk that we may not be successful in undertaking the steps currently planned in order to increase our liquidity and capital resources, resulting in inadequate funding for our planned research and development activities; and (f) other risks and uncertainties described in our filings with the Securities and Exchange Commission.

Neither management nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. All forward-looking statements in this press release are made as of the date hereof, based on information available to us as of the date hereof, and subsequent facts or circumstances may contradict, obviate, undermine, or otherwise fail to support or substantiate such statements. We caution you not to rely on these statements without also considering the risks and uncertainties associated with these statements and our business that are addressed in our filings with the Securities and Exchange Commission that are available on the SEC's web site located at www.sec.gov. Certain information included in this press release may supersede or supplement forward-looking statements in our other Exchange Act reports filed with the SEC. We assume no obligation to update any forward-looking statement to conform such statements to actual results or to changes in our expectations, except as required by applicable law or regulation.